These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. [Proliferative vitreoretinopathy. On the significance of protein transfer through the blood-retina barrier]. Grisanti S; Wiedemann P; Heimann K Ophthalmologe; 1993 Oct; 90(5):468-71. PubMed ID: 8219633 [TBL] [Abstract][Full Text] [Related]
31. The role of thrombin in proliferative vitreoretinopathy. Bastiaans J; van Meurs JC; Mulder VC; Nagtzaam NM; Smits-te Nijenhuis M; Dufour-van den Goorbergh DC; van Hagen PM; Hooijkaas H; Dik WA Invest Ophthalmol Vis Sci; 2014 Jul; 55(7):4659-66. PubMed ID: 25015355 [TBL] [Abstract][Full Text] [Related]
32. Aclacinomycin A in the treatment of experimental proliferative vitreoretinopathy. Efficacy and toxicity in the rabbit eye. Steinhorst UH; Chen EP; Hatchell DL; Samsa GP; Saloupis PT; Westendorf J; Machemer R Invest Ophthalmol Vis Sci; 1993 Apr; 34(5):1753-60. PubMed ID: 8473115 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of daunorubicin encapsulated in liposome for the treatment of proliferative vitreoretinopathy. Shinohara K; Tanaka M; Sakuma T; Kobayashi Y Ophthalmic Surg Lasers Imaging; 2003; 34(4):299-305. PubMed ID: 12875458 [TBL] [Abstract][Full Text] [Related]
34. Clinical management of proliferative vitreoretinopathy: an update. Khan MA; Brady CJ; Kaiser RS Retina; 2015 Feb; 35(2):165-75. PubMed ID: 25602631 [TBL] [Abstract][Full Text] [Related]
35. Analysis of the molecular biologic milieu of the vitreous in proliferative vitreoretinopathy. Wladis EJ; Falk NS; Iglesias BV; Beer PM; Gosselin EJ Retina; 2013 Apr; 33(4):807-11. PubMed ID: 23222459 [TBL] [Abstract][Full Text] [Related]
36. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Charteris DG; Aylward GW; Wong D; Groenewald C; Asaria RH; Bunce C; Ophthalmology; 2004 Dec; 111(12):2240-5. PubMed ID: 15582080 [TBL] [Abstract][Full Text] [Related]
38. Inhibition of retinal pigment epithelial cell-induced tractional retinal detachment by disintegrins, a group of Arg-Gly-Asp-containing peptides from viper venom. Yang CH; Huang TF; Liu KR; Chen MS; Hung PT Invest Ophthalmol Vis Sci; 1996 Apr; 37(5):843-54. PubMed ID: 8603869 [TBL] [Abstract][Full Text] [Related]
39. Ultrastructural studies of the blood-retina barrier after exposure to interleukin-1 beta or tumor necrosis factor-alpha. Claudio L; Martiney JA; Brosnan CF Lab Invest; 1994 Jun; 70(6):850-61. PubMed ID: 8015289 [TBL] [Abstract][Full Text] [Related]
40. [Vitreous substitutes as drug release systems]. Szurman P; Frank C; Kaczmarek RT; Spitzer MS Klin Monbl Augenheilkd; 2009 Sep; 226(9):718-24. PubMed ID: 19750422 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]